Whether you are developing a new monoclonal antibody (mAb), cell therapy, gene therapy, or large-molecule biologic drug, the decision to tackle GMP manufacturing in-house or work with a contract development and manufacturing organization (CDMO) represents a pivotal crossroads in your product’s journey to market.
In this article, some key considerations are discussed to help determine which strategy best suits your process, product, and team.